PSTV Plus Therapeutics, Inc. Stock Quote

PSTV [NASD]

Index	-	P/E	-	EPS (ttm)	-1.79	Insider Own	0.10%	Shs Outstand	5.37M	Perf Week	-12.58%
Market Cap	60.19M	Forward P/E	-	EPS next Y	-1.40	Insider Trans	26.84%	Shs Float	4.51M	Perf Month	12.45%
Income	-8.20M	PEG	-	EPS next Q	-0.41	Inst Own	2.30%	Short Float	3.42%	Perf Quarter	26.64%
Sales	0.30M	P/S	200.63	EPS this Y	32.90%	Inst Trans	-12.50%	Short Ratio	0.17	Perf Half Y	11.98%
Book/sh	0.56	P/B	4.84	EPS next Y	17.20%	ROA	-56.20%	Target Price	-	Perf Year	38.97%
Cash/sh	0.37	P/C	7.25	EPS next 5Y	-	ROE	-364.80%	52W Range	0.93 - 5.42	Perf YTD	34.16%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-103.10%	52W High	-50.00%	Beta	0.43
Dividend %	-	Quick Ratio	1.10	Sales past 5Y	-51.80%	Gross Margin	-	52W Low	191.08%	ATR	0.42
Employees	12	Current Ratio	1.10	Sales Q/Q	-100.00%	Oper. Margin	-	RSI (14)	45.03	Volatility	10.89% 14.61%
Optionable	No	Debt/Eq	2.10	EPS Q/Q	-384.00%	Profit Margin	-	Rel Volume	0.30	Prev Close	2.61
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 22 AMC	Payout	-	Avg Volume	910.78K	Price	2.71
Recom	1.70	SMA20	-12.65%	SMA50	4.08%	SMA200	12.41%	Volume	272,623	Change	3.83%

Jan-25-21

Initiated

Ladenburg Thalmann

Buy

Oct-16-20

Initiated

Maxim Group

Buy

Mar-02-21 07:30AM	Nextech Successfully Launches its Ad Network Featuring Augmented Reality Capabilities on its Virtual Events Properties, Delivering Millions of Impressions Business Wire
Mar-01-21 07:30AM	Nextech AR Solutions to Present at the Emerging Growth Conference on March 3, 2021 Business Wire -8.42%
07:30AM	Emerging Growth Conference 2 Announced for March 3, 2021 Niche Companies in Technology, AR, eCommerce, Beverage and more in Attendance GlobeNewswire
Feb-22-21 04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights GlobeNewswire
02:45PM	Plus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-11-21 04:15PM	Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 2021 GlobeNewswire -9.33%
07:30AM	Plus Therapeutics to Participate in BIO CEO & Investor Digital Conference GlobeNewswire
Jan-11-21 10:11AM	5 Value Stocks To Watch In The Healthcare Sector Benzinga
Jan-05-21 04:15PM	Plus Therapeutics to Participate in Upcoming January Conferences GlobeNewswire
Dec-15-20 07:30AM	Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT Glioblastoma Trial GlobeNewswire
Dec-08-20 07:30AM	Plus Therapeutics to Present at 13th Annual LD Micro Main Event Conference GlobeNewswire
Dec-01-20 07:30AM	Plus Therapeutics Expands ReSPECT Clinical Trial to MD Anderson Cancer Center GlobeNewswire
Nov-19-20 08:00AM	Plus Therapeutics Announces Positive Interim Data from ReSPECT Phase 1 Clinical Trial in Recurrent Glioblastoma GlobeNewswire -6.01%
Nov-16-20 08:00AM	Plus Therapeutics to Participate in Upcoming November Investor Conferences GlobeNewswire
Nov-13-20 07:30AM	Plus Therapeutics Announces Webinar to Present ReSPECT Glioblastoma Clinical Trial Update GlobeNewswire
Nov-12-20 07:25AM	Plus Therapeutics to Present at the virtual Fall Investor Summit on November 16th-18th ACCESSWIRE
Nov-05-20 07:00AM	Plus Therapeutics Announces Formation of Scientific Advisory Board GlobeNewswire
Oct-29-20 07:00AM	Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT Glioblastoma Trial GlobeNewswire
Oct-22-20 04:05PM	Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights GlobeNewswire +6.15%
03:00PM	Plus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-15-20 07:00AM	Plus Therapeutics to Present at the Cancer Innovation Summit GlobeNewswire
Oct-14-20 04:15PM	Plus Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on October 22, 2020 GlobeNewswire
Oct-02-20 07:00AM	Plus Therapeutics Announces Brain Cancer Clinical Advisory Team GlobeNewswire
Oct-01-20 07:00AM	ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting GlobeNewswire
Sep-15-20 07:00AM	Plus Therapeutics Receives Fast Track Designation From FDA for Its Novel Glioblastoma Treatment GlobeNewswire +24.18%
Sep-09-20 07:00PM	Plus Therapeutics, Inc. to Present at the 22nd H. C. Wainwright Annual Global Investor Conference on September 15, 2020 GlobeNewswire
Sep-03-20 07:00AM	Plus Therapeutics, Inc. to Present at the 9th Annual Gateway Conference on September 10, 2020 GlobeNewswire -7.37%
Sep-01-20 07:00AM	Plus Therapeutics, Inc. receives FDA Orphan Drug Designation for its Novel Glioblastoma Treatment GlobeNewswire +15.51%
Aug-28-20 07:00AM	Plus Therapeutics, Inc. to Present at The LD 500 Virtual Conference GlobeNewswire
Aug-25-20 10:31AM	How Much Did Plus Therapeutics' (NASDAQ:PSTV) CEO Pocket Last Year? Simply Wall St.
Aug-10-20 07:43AM	Plus Therapeutics Reports Second Quarter 2020 Financial and Business Results GlobeNewswire -5.68%
Aug-03-20 07:00AM	Plus Therapeutics To Report Second Quarter Fiscal Year 2020 Financial Results And Corporate Update on August 10, 2020 GlobeNewswire +7.00%
Jul-28-20 07:00AM	Plus Therapeutics Completes Fifth Dose Escalation Cohort of the ReSPECT Glioblastoma Clinical Trial and Expands Trial Sites GlobeNewswire +7.91%
Jul-23-20 05:00PM	Plus Therapeutics to Present at the YAFO Access China Partnering Conference on July 30, 2020 GlobeNewswire
Jul-06-20 08:01AM	Plus Therapeutics Announces Inducement Stock Grants GlobeNewswire +8.96%
May-14-20 04:27PM	Plus Therapeutics Reports First Quarter 2020 Financial and Business Results GlobeNewswire +17.69%
May-12-20 08:57AM	Plus Therapeutics Announces Patient-Focused Presentation Supporting Brain Tumor Awareness Month GlobeNewswire +23.03%
May-11-20 06:00AM	Plus Therapeutics Announces Closing of Agreement To License Novel Oncology Platform GlobeNewswire
May-07-20 04:15PM	Plus Therapeutics To Report First Quarter Fiscal Year 2020 Financial Results and Corporate Update on May 14, 2020 GlobeNewswire
Apr-16-20 04:15PM	Plus Therapeutics to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020 ACCESSWIRE -5.49%
Apr-06-20 07:00AM	Plus Therapeutics Donates Personal Protective Equipment to Scripps Health to Confront COVID-19 Pandemic GlobeNewswire +10.49%
Apr-01-20 07:00AM	Plus Therapeutics Announces Dr. Gregory Stein as Head of Clinical Development GlobeNewswire -9.57%
Mar-30-20 04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Fiscal Year 2019 Financial and Business Results GlobeNewswire +57.64%
03:00PM	Plus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
07:15AM	Plus Therapeutics Licenses Novel Oncology Platform, Expands Pipeline GlobeNewswire
Mar-25-20 05:53PM	Plus Therapeutics To Report Fourth Quarter and Full Fiscal Year 2019 Financial Results and Corporate Update on March 30, 2020 GlobeNewswire +7.69%
Mar-12-20 07:15AM	Plus Therapeutics Welcomes Two New Directors GlobeNewswire -22.54%
Feb-06-20 05:00PM	Plus Therapeutics Appoints Chief Financial Officer GlobeNewswire
05:00PM	Plus Therapeutics Announces Changes to its Board of Directors GlobeNewswire
Jan-06-20 07:15AM	Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020 GlobeNewswire
Jan-02-20 04:15PM	Plus Therapeutics Appoints Dr. An van Es-Johansson to Board of Directors GlobeNewswire +10.42%
Dec-09-19 07:00AM	Plus Therapeutics to Present at Biotech Showcase 2020 GlobeNewswire +7.42%
Nov-25-19 07:00AM	Plus Therapeutics to Present at the LD Micro Main Event (XII) GlobeNewswire
Nov-14-19 04:05PM	Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results GlobeNewswire
Nov-04-19 07:00AM	Plus Therapeutics To Report Fiscal 2019 Third Quarter Financial Results and Corporate Update on November 14, 2019 GlobeNewswire
Oct-15-19 09:20AM	Plus Therapeutics Receives $4.6MM Reimbursement Payment GlobeNewswire +12.24%
Sep-26-19 04:10PM	Plus Therapeutics, Inc. Announces Closing of $15 Million Underwritten Public Offering GlobeNewswire
Sep-23-19 12:15PM	Plus Therapeutics, Inc. Announces Pricing Of $15 Million Underwritten Public Offering GlobeNewswire -49.50%
06:10AM	Plus Therapeutics to Receive $4.6MM Reimbursement Payment GlobeNewswire

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HEDRICK MARC H	Chief Executive Officer	Dec 10	Buy	1.99	2,500	4,975	13,867	Dec 14 06:05 AM
HEDRICK MARC H	Chief Executive Officer	Nov 30	Buy	2.14	2,200	4,708	11,367	Dec 02 07:00 AM
Lenk Robert P	Director	Aug 25	Buy	2.49	3,000	7,465	3,000	Aug 26 06:05 AM
Petersen Greg	Director	Aug 13	Buy	2.80	10,000	28,000	20,000	Aug 14 06:05 AM
Petersen Greg	Director	Aug 12	Buy	2.52	10,000	25,200	10,000	Aug 13 06:05 AM
HEDRICK MARC H	Chief Executive Officer	Aug 12	Buy	2.58	4,000	10,318	9,167	Aug 13 06:00 AM
HEDRICK MARC H	Chief Executive Officer	Jun 22	Buy	2.10	5,000	10,500	5,167	Jun 23 07:10 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience